Search Within

Department of Medicine

Formats
  1. Journal Article (19590)
  2. Meeting Abstract (16038)
  3. Review (1149)
  4. Book Section (934)
  5. Editorial (607)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22319)
  2. Hematologic Malignancies, Division of (13274)
  3. Center for Hematologic Malignancies (11058)
  4. GSK Faculty (10645)
  5. Survivorship Research (9329)
  6. Division of Subspecialty Medicine (7534)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1064)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4215)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2110)

More Publishers

Results (39615)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or Dara-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis
    Meeting Abstract

    Hagen, P.; Sidana, S.; Parker, T. L.; Walker, B. A.; Sanchorawala, V.; Zonder, J. A.; Kourelis, T.; D'Souza, A.; Landau, H. J.; Rosenthal, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Optimizing therapeutic outcome of CD19(T2)28z1XX chimeric antigen receptor (CAR) T in adult patients with large B-cell lymphoma through a quantitative medicine approach
    Meeting Abstract

    Dey, A.; Li, J.; Park, J. H.; Sellner, L.; Sundaresan, V.; Palomba, M. L.; Mansilla-Soto, J.; Senechal, B.; Wang, X.; Sikder, D. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Bridging radiotherapy may decrease inflammation prior to CAR-T cell therapy
    Meeting Abstract

    Patel, R. R.; Tward, A.; Fregonese, B.; Hubbeling, H.; Lapen, K.; Mankuzhy, N. P.; Raj, S. S.; Perales, M. A.; Shouval, R.; Yahalom, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Confirmatory efficacy and safety evaluation of MB-105, a CD5.CAR T therapy: Multicenter phase 2 study in patients with relapsed/refractory T cell lymphoma (R/R TCL)
    Meeting Abstract

    Iyer, S. P.; Hill, L.; Horwitz, S.; Jain, S.; Poh, C.; Vose, J. M.; Brenner, M. K.; Mamonkin, M.; Hein, S.; Giordano, F.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 2B, open-label multicenter study of tebapivat (AG-946), a potent pyruvate kinase activator, in patients
    Meeting Abstract

    Zeidan, A. M.; Sekeres, M. A.; Al-Samkari, H.; Carraway, H. E.; DeZern, A. E.; Mittelman, M.; Little, M.; Beynon, V.; Dai, X.; Sommakia, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • First results of asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors for patients with chronic myeloid leukemia who do not achieve a deep molecular remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)
    Meeting Abstract

    Cortes, J. E.; Mauro, M. J.; Visotcky, A.; Tantravahi, S. K.; Thompson, J. E.; Yang, J.; Baim, A.; Gao, Y.; Maldonado-Schmidt, S.; Olig, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Zeidan, A. M.; Stein, E. M.; Mauro, M. J.; Podoltsev, N. A.; Rampal, R.
    Blood (2024)

    Fulltext@MSK | Save
  • Cardinal: A phase I, multicenter, open-label, dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in chronic myeloid leukemia
    Meeting Abstract

    Jabbour, E.; Rea, D.; Cortes, J. E.; Hochhaus, A.; Hughes, T. P.; Kim, D. W.; Kantarjian, H. M.; Holes, L.; Kuriakose, E. T.; Mauro, M. J.
    Blood (2024)

    Fulltext@MSK | Save